The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | A Phase I/II study evaluating MS-553 in patients with CLL/SLL
James Blachly, MD, The Ohio State University, Columbus, OH, discusses the trial design of a study which is investigating the efficacy of MS-553, a protein kinase C (PKC) β inhibitor, in refractory patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (NCT03492125). Dr Blachly highlights that the study consists of three cohorts: MS-553 monotherapy, MS-553 in combination with acalabrutinib, and MS-553 with venetoclax plus an anti-CD20 antibody. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
MingSight Pharmaceuticals: Research Funding; AstraZeneca: Consultancy, Membership on an entity’s Board of Directors or advisory committees; INNATE Pharma: Consultancy, Membership on an entity’s Board of Directors or advisory committees; KITE Pharma: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Astellas: Consultancy, Membership on an entity’s Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity’s Board of Directors or advisory committees.
